

1 SUBMITTED 22 JAN 24  
2 REVISION REQ. 18 MAR 24; REVISION RECD. 21 MAR 24  
3 ACCEPTED 26 MAR 24  
4 **ONLINE-FIRST: JUNE 2024**  
5 **DOI: <https://doi.org/10.18295/squmj.6.2024.035>**

## Septum Pellucidum Cavernous Malformation

### *A rare entity*

Asma AlHatmi,<sup>1</sup> Rajeev Kariyattil,<sup>2</sup> \*Eiman Al-Ajmi<sup>1</sup>

Departments of <sup>1</sup>Radiology & Molecular Imaging and <sup>2</sup>Surgery, Sultan Qaboos University  
Hospital, Sultan Qaboos University, Muscat, Oman

\*Corresponding Author's e-mail: [ealajmi@squ.edu.om](mailto:ealajmi@squ.edu.om)

A 30-year-old man with no medical background presented to the emergency department in 2022 at a tertiary care hospital, Muscat, Oman, with a one-week history of persistent headache and a few episodes of vomiting. There was no history of seizure, visual symptoms, neurological deficit or loss of consciousness. On examination, he was fully conscious and alert. His neurological examination was unremarkable. The ophthalmology examination was normal with no evidence of papilledema. Computed tomography (CT) showed a well-defined hyperdense lesion in the septum pellucidum bulging bilaterally to the lateral ventricles and minimal dilatation of the lateral ventricles with no signs of acute hydrocephalus. Magnetic resonance imaging (MRI) of the brain was done and revealed a well-circumscribed lesion in the septum pellucidum with a heterogeneous signal intensity and hypointense rim of hemosiderin and an internal bubbly appearance, forming a “popcorn” appearance in T2-weighted images. Significant blooming in T2\* gradient echo images was present at the site of the lesion, denoting blood products (**Figure 1**). There was no enhancement in the lesion, and there was no surrounding edema, significant mass effect, or intraventricular hemorrhage. These imaging findings favored the diagnosis of the septum pellucidum cavernous malformation. As there was no objective clinical evidence of raised intracranial pressure (ICP) or radiological evidence of acute bleeding or ventricular obstruction, he was managed conservatively. He remained asymptomatic, and a follow-up MRI

32 after eighteen months showed an interval reduction in the size of the lesion with a siderotic rim  
33 and internal old blood products (**Figure 2**). The patient will have an annual MRI of the brain for  
34 next two years, and he was instructed to report any new symptoms promptly.

35

36 We present a case of septum pellucidum cavernoma, its imaging features, differential diagnosis,  
37 and treatment options. Septum pellucidum cavernoma is an extremely rare entity, with only  
38 several similar cases reported in the literature.

39

40 Informed written consent for the publication was obtained from the patient.

41

#### 42 **Comment**

43 Cerebral cavernous malformations, or cavernomas, are one of the central nervous system (CNS)  
44 vascular malformations with an overall prevalence of 0.02-13%. Among CNS vascular  
45 malformations, it is the third most common after developmental venous anomaly (DVA) and  
46 capillary telangiectasia, forming 5–13% of cases.<sup>1,2</sup> CNS cavernomas can be sporadic or familial.  
47 Positive family history, prior radiotherapy, or head trauma are considered the major risk factors  
48 for acquired cavernomas.<sup>1,3</sup> Cavernomas can be solitary or multiple, especially in hereditary  
49 types. It can also be associated with other vascular malformations, most commonly is DVA.<sup>1</sup>  
50 Around 50% of CNS cavernomas are incidental. It has a wide range of clinical presentations  
51 depending on location, size, and associated complications like mass effect or hemorrhage.<sup>2,4</sup> 74  
52 to 90% of cerebral cavernomas are seen in supratentorial location.<sup>1,2</sup> Headache, seizure, and  
53 focal neurological deficits are commonly associated with supratentorial cavernomas compared to  
54 bleeding, which is commonly seen in infratentorial cavernomas.<sup>2</sup>

55

56 Intraventricular cavernomas are rare and seen in less than 10% of cases.<sup>5</sup> Septum pellucidum  
57 cavernoma is an extremely rare subtype of intraventricular cavernoma.<sup>1,2</sup> Septum pellucidum is a  
58 thin midline anatomical sheet seen between the anterior horn of lateral ventricles and extending  
59 from the corpus callosum to the fornix, which is an important structure connecting the  
60 hippocampus and other parts involved in memory function.<sup>1</sup> Furthermore, bleeding within the  
61 septum pellucidum cavernoma may damage the fornix and lead to long-term memory  
62 impairment and anterograde amnesia.<sup>1,4</sup> Septum pellucidum cavernomas can also extend to either

63 side of lateral ventricle and may lead to hydrocephalus secondary to compression on the foramen  
64 of Monro.<sup>4</sup> Haque et al. published a review article and descriptive analysis of septum pellucidum  
65 cavernoma that included ten cases found in English literature.<sup>1</sup> The median age at diagnosis was  
66 42 years and majority of them were males. The most common presentation was headache seen in  
67 70% of cases and 20% presented with impaired memory. One third of the included patients  
68 presented with complications like hemorrhage and hydrocephalus.<sup>1</sup>

69  
70 Neuroimaging plays an important role in the diagnosis. Large cavernomas are seen as  
71 hyperdense lesions on CT. Small cavernomas can be difficult to visualize on CT.<sup>4</sup> MRI, on the  
72 other hand provides superior assessment in these cases. MRI shows the characteristic "popcorn"  
73 or "berry" appearance with a rim of hemosiderin as seen in our patient.<sup>1</sup> The signal intensity is  
74 variable depending on the age of the blood products. In lesions that bled recently, surrounding  
75 oedema may be seen. T2\* gradient echo images, or susceptibility-weighted imaging (SWI), is the  
76 best sequence for detecting small cavernomas, particularly in the hereditary type. The  
77 enhancement is variable, ranging from none to a moderate degree of enhancement.<sup>1,2</sup> On digital  
78 subtraction angiography, cavernomas are occult lesions due to the lack of arteriovenous shunts.<sup>1</sup>

79  
80 The differential diagnosis for septum pellucidum cavernomas includes hematoma, arteriovenous  
81 malformation, colloid cyst, neurocysticercosis, or other neoplastic lesions, especially when  
82 associated with hemorrhage or calcifications like central neurocytoma, ependymoma, and  
83 subependymal giant cell astrocytoma.<sup>1,2,5</sup>

84  
85 The management of CNS cavernomas depends on the location and symptoms. Asymptomatic  
86 lesions can be managed conservatively. Symptomatic lesions due to mass effect, epilepsy, focal  
87 neurological deficit, and repeated hemorrhage necessitate surgical intervention. Cavernomas of  
88 the septum pellucidum with established or imminent ventricular obstruction warrant prompt  
89 surgical intervention. Different surgical approaches were reported, but the most common method  
90 is transcranial transcallosal anterior interhemispheric approach.<sup>1,2,4</sup> Although neuroendoscopy is  
91 a minimally invasive procedure with fewer complications, its role in the excision of septum  
92 pellucidum cavernoma is questionable and unclear due to the possible difficulty of controlling  
93 the bleeding.<sup>1</sup> The role of radiotherapy is debatable and is used for symptomatic control of some

94 intraparenchymal cavernomas.<sup>5</sup> Some studies believe that radiation increases the risk of  
95 cavernomas bleeding, interval growth, and recurrence.<sup>1,3</sup> Complete surgical resection of septum  
96 pellucidum cavernomas is curative, with clinical improvement and no recurrence.<sup>1,3</sup> Few cases  
97 reported persistent memory impairments that were present at the time of diagnosis which could  
98 be attributed to irreversible damage to the fornix.<sup>1,3</sup>

#### 100 **Authors' Contribution**

101 AA collected the clinical data, reviewed literature and drafted the manuscript. RK reviewed the  
102 clinical aspects of the case description and reviewed the manuscript. EA supervised the work,  
103 selected the representative images and critically reviewed the manuscript. All authors approved  
104 the final version of the manuscript.

#### 106 **References:**

- 107 1. Haque S, Islam A, Rahman T, Hossain MD, Siddik AB, Shourav MMI, Hasan MF, Ikram  
108 S, Rahman M. Cavernoma in septum pellucidum: descriptive analysis and review of existing  
109 literature. medRxiv; 2021. DOI: 10.1101/2021.02.18.21252024.
- 110 2. Paiva A, Lovato RM, Araujo JO, Veiga J. Septum Pellucidum Cavernoma: A Case Report and  
111 Anatomical Consideration of an Extremely Rare Lesion. Turk Neurosurg. 2020;30(1):145-148.  
112 doi:10.5137/1019-5149.JTN.23793-18.3.
- 113 3. Picolas C, Faropoulos K, Kekempanou K, Gatzounis G. Case Report of a Septum Pellucidum  
114 Cavernoma Surgically Resected via Inferior Parietal Approach and Short Literature Review.  
115 Open J Mod Neurosurg, 2016; 6, 68-75. DOI: 10.4236/ojmn.2016.62013.
- 116 4. Muzumdar D, Avinash KM, Ramdasi R. Cavernoma of the septum pellucidum in the region of  
117 foramen of Monro. Neurol India 63 (2015): 68-71. DOI: 10.4103/0028-3886.152641.
- 118 5. Faropoulos K, Panagiotopoulos V, Partheni M, Tzortzidis F, Konstantinou D. Therapeutic  
119 management of intraventricular cavernoma: case series and review of the literature. J Neurol  
120 Surg A Cent Eur Neurosurg. 2015;76(3):233-239. doi:10.1055/s-0034-1389093.


121

122

123


124

125



126  
127  
128  
129  
130  
131  
132

**Figure 1:** (A) Axial non-enhanced CT image shows a hyperdense lesion of the septum pellucidum at the level of the frontal horns bulging bilaterally to the lateral ventricles. (B) axial T2 weighted image shows the lesion to be T2 hyperintense with a bubbly appearance. (C) T2\* gradient echo image shows significant blooming at the site of the lesion. (D) Post-contrast axial T1-weighted image shows no significant enhancement.



133

134

135

136

**Figure 2:** MRI follow-up after 18 months shows (A) interval reduction in the size of the lesion with a siderotic rim in axial T2, and (B) susceptibility effects due to old blood products in susceptibility-weighted imaging.

Accepted Article